View Author
patient virus resistance mutation study infection treatment therapy hbsag fluenza response protease level hepatitis analysis sequence result transmission inhibitor drug resistance hepatitis b protein network pandemic group subtype population assay prevalence sample failure decline baseline antiretroviral influenza oseltamivir table relation variant system netherland monotherapy neuraminidase change university serum tropism interaction score number trial disease virological lopinavir peg-ifn plasma model hbsag decline figure individual method regimen genotypic zanamivir hbeag-negative i 223r replication hiv infection animal tenofovir value hbv dna virological failure position hbv dna levels reduction combination testing drug-resistant signi
10 Most Recent Publications
|
Global assessment of resistance to neuraminidase inhibitors, 2008-2011: The influenza resistance information study (IRIS)
(Article)
Whitley, R.D. Boucher, C.A.B. Lina, B. Nguyen-Van-Tam, J.S. Osterhaus, A.D.M.E. Schutten, M. Monto, A. |
2013-05-01
|
|
Cost-Effectiveness of Pre-Exposure Prophylaxis (PrEP) in Preventing HIV-1 Infections in Rural Zambia: A Modeling Study
(Article)
Nichols, B.E. Boucher, C.A.B. Dijk, F.J.H. van Thuma, P.E. Nouwen, J.L. Baltussen, R.M.P.M. Wijgert, J. van de Sloot, P.M.A. Vijver, D.A.M.C. van de |
2013-03-18
|
|
Deep sequencing does not reveal additional transmitted mutations in patients diagnosed with HIV-1 variants with single nucleoside reverse transcriptase inhibitor resistance mutations
(Article)
Pingen, M. Ende, M.E. van der Wensing, A.M.J. El Barzouhi, A. Simen, B. Schutten, M. Boucher, C.A.B. |
2013-03-01
|
|
Incidence of viral respiratory pathogens causing exacerbations in adult cystic fibrosis patients
(Article)
Hoek, R.A.S. Paats, M.S. Pas, S.D. Bakker, M. Hoogsteden, H.C. Boucher, C.A.B. Eerden, M. van der |
2013-01-01
|
|
Identification and treatment of chronic hepatitis B in Chinese migrants: Results of a project offering on-site testing in Rotterdam, the Netherlands
(Article)
Veldhuizen, I.K. Wolter, R. Rijckborst, V. Mostert, M.C. Voeten, H.A.C.M. Cheung, Y.M. Boucher, C.A.B. Reijnders, J.G.P. Zwart, O. de Janssen, H.L.A. |
2012-12-01
|
|
Therapy failure resulting from superinfection by a drug-resistant HIV variant
(Article)
Pingen, M. Nouwen, J.L. Schutten, M. Boucher, C.A.B. Dinant, S. Albert, J. Mild, M. Brodin, J. Simen, B.B. Walsh, S. Kayser, M. Ende, M.E. van der |
2012-12-01
|
|
Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon α-2a: Progressive decrease in hepatitis B surface antigen in responders
(Article)
Rijckborst, V. Ferenci, P. Vuuren, A.J. van Boucher, C.A.B. Hansen, B.E. Janssen, H.L.A. Akdogan, M. Pinarbasi, B. Borg, M.J. ter Simon, K. Flisiak, R. Akarca, U.S. Raptopoulou-Gigi, M. Verhey, E. |
2012-09-01
|
|
H1N1 2009 Pandemic Influenza Virus: Resistance of the I223R Neuraminidase Mutant Explained by Kinetic and Structural Analysis
(Article)
Vries, E. van der Collins, P.J. Martin, S.R. Boucher, C.A.B. Skehel, J.J. Gamblin, S.J. Vachieri, S.G. Xiong, X. Liu, J. Walker, P.A. Haire, L.F. Hay, A.J. Schutten, M. Osterhaus, A.D.M.E. |
2012-09-01
|
|
Aciclovir for dual infection with HIV and HSV
(Article)
Verjans, G.M.G.M. Boucher, C.A.B. |
2012-06-01
|
|
Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: Relation to response and HBV genotype
(Article)
Sonneveld, M.J. Rijckborst, V. Janssen, H.L.A. Cakaloglu, Y. Simon, K. Heathcote, E.J. Tabak, F. Mach, T. Boucher, C.A.B. Hansen, B.E. Zeuzem, S. |
2012-01-30
|
